International Journal of Clinical Oncology

, Volume 18, Issue 3, pp 492–497 | Cite as

The relationship between urinary bisphenol A levels and meningioma in Chinese adults

  • Bo Duan
  • Xuebin Hu
  • Hongyang Zhao
  • Jun Qin
  • Jie Luo
Original Article

Abstract

Background

Estrogen has been implicated as a risk factor for meningioma. Bisphenol A (BPA), a widely used synthetic xenoestrogen, has already been reported to be associated with several estrogen-sensitive tumors.

Method

An exploratory association study of 243 meningioma cases and 258 frequency-matched healthy controls was conducted, using subjects from a hospital-based study to demonstrate the association of urine BPA concentration and the risk of meningioma. The specimens and data of patients were collected at Union Hospital, Wuhan, China, from 2009 to 2010.

Results

A positive association between increasing levels of urinary BPA and meningioma was observed, independent of confounding factors such as gender, age, race, body mass index, HRT use, BMI, and family history of cancer. Compared to quartile 1 (referent), the multivariate-adjusted odds ratio of meningioma associated with quartile 4 was 1.45 (95 % CI, 1.02–1.98) (P trend = 0.03).

Conclusion

In this case–control study from China, a clear association between urinary BPA concentrations and diagnosis of meningioma was detected.

Keywords

Urinary bisphenol A Meningioma Neurosurgery 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (grant NSFC-30871386).

Conflict of interest

No author has any conflict of interest.

References

  1. 1.
    Longstreth WT, Dennis LK, McGurire VM et al (1993) Epidemiology of intracranial meningioma. Cancer (Phila) 72:639–648CrossRefGoogle Scholar
  2. 2.
    Sadetzki S, Flint-Richter P, Ben-Tal T et al (2002) Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg 97:1078–1082PubMedCrossRefGoogle Scholar
  3. 3.
    Alexiou GA, Markoula S, Gogou P et al (2011) Genetic and molecular alterations in meningiomas. Clin Neurol Neurosurg 113:261–267PubMedCrossRefGoogle Scholar
  4. 4.
    Whittle IR, Smith C, Navoo P et al (2004) Meningiomas. Lancet 363:1535–1543PubMedCrossRefGoogle Scholar
  5. 5.
    Roelvink NC, Kamphorst W, van Alphen HA et al (1987) Pregnancy-related primary brain and spinal tumors. Arch Neurol 44:209–215PubMedCrossRefGoogle Scholar
  6. 6.
    Schoenberg BS, Christine BW, Whisnant JP (1975) Nervous system neoplasms and primary malignancies of other sites. The unique association between meningiomas and breast cancer. Neurology 25:705–712PubMedCrossRefGoogle Scholar
  7. 7.
    Carroll RS, Zhang J, Black PM (1999) Expression of estrogen receptors alpha and beta in human meningiomas. J Neurooncol 42:109–116PubMedCrossRefGoogle Scholar
  8. 8.
    Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120PubMedCrossRefGoogle Scholar
  9. 9.
    Speirs V, Boyle-Walsh E, Fraser WD (1997) Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. Int J Cancer 72:714–719PubMedCrossRefGoogle Scholar
  10. 10.
    Michaud DS, Gallo V, Schlehofer B et al (2010) Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev 19:2562–2569PubMedCrossRefGoogle Scholar
  11. 11.
    Pines A (2010) Hormone therapy and brain tumors. Climacteric 14:215–216PubMedCrossRefGoogle Scholar
  12. 12.
    Blitshteyn S, Crook JE, Jaeckle KA (2008) Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 26:279–282PubMedCrossRefGoogle Scholar
  13. 13.
    Claus EB, Black PM, Bondy ML et al (2007) Exogenous hormone use and meningioma risk: what do we tell our patients? Cancer (Phila) 110:471–476CrossRefGoogle Scholar
  14. 14.
    Calafat AM, Ye X, Wong LY et al (2008) Exposure of the U.S. population to bisphenol A and 4-tertiary-octylphenol: 2003–2004. Environ Health Perspect 116:39–44PubMedCrossRefGoogle Scholar
  15. 15.
    Rubin BS (2011) Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 127:27–34PubMedCrossRefGoogle Scholar
  16. 16.
    Kundakovic M, Champagne FA (2011) Epigenetic perspective on the developmental effects of bisphenol A. Brain Behav Immun 25:1084–1093PubMedCrossRefGoogle Scholar
  17. 17.
    Wolstenholme JT, Rissman EF, Connelly JJ (2010) The role of bisphenol A in shaping the brain, epigenome and behavior. Horm Behav 59:296–305PubMedCrossRefGoogle Scholar
  18. 18.
    Okada H, Tokunaga T, Liu X et al (2008) Direct evidence revealing structural elements essential for the high binding ability of bisphenol A to human estrogen-related receptor-gamma. Environ Health Perspect 116:32–38PubMedCrossRefGoogle Scholar
  19. 19.
    Matsushima A, Kakuta Y, Teramoto T et al (2007) Structural evidence for endocrine disruptor bisphenol A binding to human nuclear receptor ERR gamma. J Biochem 142:517–524PubMedCrossRefGoogle Scholar
  20. 20.
    Melzer D, Harries L, Cipelli R et al (2011) Bisphenol A exposure is associated with in vivo estrogenic gene expression in adults. Environ Health Perspect 127:27–34Google Scholar
  21. 21.
    Soto AM, Vandenberg LN, Maffini MV et al (2008) Does breast cancer start in the womb? Basic Clin Pharmacol Toxicol 102:125–133PubMedCrossRefGoogle Scholar
  22. 22.
    Henderson BE, Bernstein L, Ross RK et al (1988) The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. Br J Cancer 57:216–218PubMedCrossRefGoogle Scholar
  23. 23.
    Powell IJ, Meyskens FL (2001) African American men and hereditary/familial prostate cancer: intermediate-risk populations for chemoprevention trials. Urology 57:178–181PubMedCrossRefGoogle Scholar
  24. 24.
    Timms BG, Howdeshell KL, Barton L et al (2005) Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc Natl Acad Sci USA 102:7014–7019PubMedCrossRefGoogle Scholar
  25. 25.
    Ho SM, Tang WY, Belmonte de Frausto J et al (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res 66:5624–5632PubMedCrossRefGoogle Scholar
  26. 26.
    Lang IA, Galloway TS, Scarlett A et al (2008) Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 300:1303–1310PubMedCrossRefGoogle Scholar
  27. 27.
    Gazzeri R, Galarza M, Gazzeri G (2007) Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 357:2411–2412PubMedCrossRefGoogle Scholar
  28. 28.
    Jay JR, MacLaughlin DT, Riley KP et al (1985) Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 62:757–762PubMedCrossRefGoogle Scholar
  29. 29.
    Vandenberg LN, Maffini MV, Sonnenschein C et al (2009) Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev 30:75–95PubMedCrossRefGoogle Scholar
  30. 30.
    Calafat AM, Kuklenyik Z, Reidy JA et al (2005) Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ Health Perspect 113:391–395PubMedCrossRefGoogle Scholar
  31. 31.
    Hiroi H, Tsutsmi O, Momoeda M et al (1999) Differential interactions of bisphenol A and 17-beta-estradiol with estrogen receptor alpha (ER-alpha) and ER-beta. Endocr J 46:773–778PubMedCrossRefGoogle Scholar
  32. 32.
    Matthews JB, Twomey K, Zacharewski TR (2001) In vitro and in vivo interactions of bisphenol A and its metabolite, bisphenol A glucuronide, with estrogen receptors alpha and beta. Chem Res Toxicol 14:149–157PubMedCrossRefGoogle Scholar
  33. 33.
    Lewis JB, Lapp CA, Schafer TE et al (2000) 4-Hydroxytamoxifen-induced cytotoxicity and bisphenol A: competition for estrogen receptors in human breast cancer cell lines. In Vitro Cell Dev Biol Anim 36:320–326PubMedCrossRefGoogle Scholar
  34. 34.
    Lapensee EW, Tuttle TR, Fox SR et al (2009) Bisphenol A at low nanomolar doses confers chemoresistance in estrogen receptor-alpha-positive and -negative breast cancer cells. Environ Health Perspect 117:175–180PubMedGoogle Scholar
  35. 35.
    Rubin BS, Soto AM (2009) Bisphenol A: perinatal exposure and body weight. Mol Cell Endocrinol 304:55–62PubMedCrossRefGoogle Scholar
  36. 36.
    Newbold RR, Padilla-Banks E, Jefferson WN (2009) Environmental estrogens and obesity. Mol Cell Endocrinol 304:84–89PubMedCrossRefGoogle Scholar
  37. 37.
    Shankar A, Teppala S (2011) Relationship between urinary bisphenol A levels and diabetes mellitus. J Clin Endocrinol Metab 15:3455–3462Google Scholar
  38. 38.
    Benson VS, Pirie K, Green J et al (2008) Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 99:185–190PubMedCrossRefGoogle Scholar
  39. 39.
    Jhawar BS, Fuchs CS, Colditz GA et al (2003) Sex steroid hormone exposures and risk for meningioma. J Neurosurg 99:848–853PubMedCrossRefGoogle Scholar
  40. 40.
    Michaud DS, Bove G, Gallo V et al (2011) Anthropometric measures, physical activity, and risk of glioma and meningioma in a large prospective cohort study. Cancer Prev Res (Phila) 4:1385–1392CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2012

Authors and Affiliations

  • Bo Duan
    • 1
    • 2
  • Xuebin Hu
    • 1
  • Hongyang Zhao
    • 1
  • Jun Qin
    • 2
  • Jie Luo
    • 2
  1. 1.Department of Neurosurgery, Union HospitalHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Neurosurgery, Taihe HospitalHubei University of MedicineShiyanChina

Personalised recommendations